Comparing the current results to its competitors, Kronos Bio Inc reported Revenue decrease in the 1 quarter 2025 year on year by -26.03 %, despite the revenue increase by the most of its competitors of 9.6 %, recorded in the same quarter.
October 9, 2024
In the ever-evolving landscape of oncology, the role of specific targets in overcoming cancer s complex mechanisms is paramount. Recently, Kronos Bio made significant strides in this arena, presenting compelling data at the EORTC-NCI-AACR Symposium that underlined the therapeutic potential of p300 KAT inhibition in human papillomavirus (HPV)-driven tumors. This announcement specifically highlighted the efficacy of their selective p300 KAT inhibitor, KB-9558, against the HPV oncoproteins E6 and E7, which are known to play pivotal roles in tumorigenesis.Human papillomavirus, a well-documented contributor to cervical and other anogenital cancers, harbors the ability to manipulate host cellular machinery, thus f...
September 23, 2024
At the recent American Association for Cancer Research (AACR) Ovarian Cancer Research Symposium, Kronos Bio Inc. presented promising data that may pave the way for the clinical evaluation of its investigational therapy, Istisociclib, in advanced ovarian cancer. This presentation comes at a crucial time for the company, as its shares have shown a significant decline throughout the month, trailing behind the overall market.Kronos Bio’s findings at the symposium highlight the potential of Istisociclib as a viable treatment option for patients with advanced ovarian cancer, a critical area of need in oncology. The data presented underscored the drug’s mechanism of action, which targets specific pathways invol...
July 23, 2024
Kronos Bio, a prominent cancer-focused biotechnology company, has announced significant advancements in their ongoing clinical trial of KB-0742, an oral CDK9 inhibitor. The Phase 1/2 trial, KB-0742-1001, aims to evaluate the efficacy of KB-0742 in patients with relapsed or refractory transcriptionally addicted advanced solid tumors. This article provides an overview of recent developments, including the dosing schedule clearance, upcoming presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the company s strategic restructuring to bolster clinical development efforts.KB-0742 Dosing Schedule Clearance:Kronos Bio is pleased to announce that KB-0742 s 80mg four-days-on, three-da...
April 24, 2024
Kronos Bio, Inc., a leading biopharmaceutical company focused on revolutionizing cancer therapies, is set to present exciting updates on its Phase 1/2 clinical trial of KB-0742, an innovative oral CDK9 inhibitor. The presentation will take place at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting scheduled from May 31 to June 4, 2024, in Chicago, Illinois. Additionally, Kronos Bio recently announced its participation in the American Association for Cancer Research (AACR) annual meeting, held in April 2024. These events offer an opportunity for the company to share breakthroughs in cancer research and gain recognition for their groundbreaking treatments.Kronos Bio s KB-0742: A Ray o...
March 5, 2024
Kronos Bio s Presentation at AACR 2024 Annual Meeting Highlights Cutting-Edge Advances in Cancer Research San Mateo, California and Cambridge, Massachusetts - Kronos Bio, Inc. (Nasdaq: KRON), a pioneering company committed to revolutionizing cancer treatment, has set the stage for a momentous breakthrough at the upcoming American Association for Cancer Research (AACR) annual meeting. With three abstracts being presented at the event, held from April 5-10, 2024 in San Diego, California, Kronos Bio s innovative research has the potential to transform the lives of millions affected by cancer.The selected abstracts promise to unveil groundbreaking insights into the treatment of cancer, positioning Kronos Bio as ...
The business model of Blueprint Medicines Corporation revolves around the development and commercialization of precision therapies for patients with genomically defined cancers and rare diseases. They actively pursue a strategy of genomically targeted drug discovery and development, utilizing advanced technologies and clinical expertise to bring potentially life-changing treatments to market. The company focuses on creating value through strategic collaborations, licensing agreements, and the commercialization of their innovative therapies.
Erasca Inc is a biotechnology company that focuses on discovering and developing innovative therapies for cancer. Their business model revolves around leveraging cutting-edge technologies and scientific expertise to identify and advance multiple drug candidates simultaneously. By collaborating with academic institutions and biopharmaceutical partners, Erasca aims to accelerate the development of cancer treatments to improve patient outcomes.
G1 Therapeutics Inc is a biopharmaceutical company that operates under a research and development business model. They focus on discovering, developing, and commercializing novel therapies to address unmet needs in cancer treatment, with a strong emphasis on targeting specific cellular processes. Their business model involves conducting preclinical and clinical trials, obtaining regulatory approvals, and collaborating with strategic partners to bring their innovative drugs to market.
KB Home's business model involves constructing and selling single-family homes to individuals and families. They focus on delivering personalized homes through a built-to-order approach, giving homeowners the opportunity to customize their homes based on their preferences and needs.
Sources:
Kronos Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Kronos Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
